Glucotrack: notice of delisting or failure to meet a listing standard

Form 8-K filed Oct 29, 2026 · items 3.01

What the filing says

As previously disclosed, Glucotrack, Inc. (the “Company”) received a determination from The Nasdaq Stock Market LLC (“Nasdaq”) to delist the Company’s securities for failure to comply with the $1.00 minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Following a hearing, a Nasdaq Hea

Read the filing on SEC EDGAR →

What usually followsAcross 492 8-Ks reporting Item 3.01 (delisting notice or listing-rule failure) in our universe, the stock's median move the next session was 0.0% (typical size ±2.1%, up 46% of the time); over the following 21 sessions, −0.2%. Every item ranked →

What this kind of filing means

Item 3.01 — Notice of delisting or failure to meet a listing standard. A delisting notice starts a compliance window; companies often answer with a reverse split, a plan, or a move to another market.

Glucotrack’s other material 8-Ks

Oct 22, 2026 — Debt and financing Glucotrack, Inc. Announces Reverse Stock Split

Other recent delisting notices

Barfresh Food Group Nov 6, 2026
Fifth Era Acquisition Corp I Nov 6, 2026
Tempest Therapeutics Nov 6, 2026
Roku Nov 6, 2026
Bowman Consulting Group Nov 6, 2026
Knightscope Nov 6, 2026
Curis Nov 6, 2026
Intrusion Nov 5, 2026
Karyopharm Therapeutics Nov 5, 2026
Cognition Therapeutics Nov 5, 2026

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.